Why scientists are studying
if chloroquine
could treat coronavirus

A close look at why this old malaria drug could be promising for COVID-19
Bill Sullivan
March 28, 2020

As COVID-19 ravages the world, scientists are desperately trying to develop a medication to stop the virus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2). Dozens of drugs and vaccine candidates are in various stages of development and testing. Among these is chloroquine, a seemingly strange choice as it has been widely used to treat malaria since the 1940s.

Editor's note: Do not take any form of chloroquine or hydroxychloroquine without medical supervision.

Jynto/Wikimedia Commons
In this ball-and-stick model of the chloroquine molecule, carbon is black, hydrogen is white, nitrogen is blue and chlorine is green.

Not only is chloroquine effective in treating malaria, it is inexpensive to make and remarkably well-tolerated by most patients (though it poses the same dangers all medications do if taken without the oversight of a doctor). It was such a good drug in the battle against malaria that it was overused, facilitating the emergence of malaria parasites that are resistant to it.

Malaria is caused by a single-celled parasite called Plasmodium. After a mosquito harboring the parasites bites a victim, the parasites make their way to the liver and eventually the red blood cells. Inside red blood cells, the parasites use the hemoglobin as a food source, which is digested in the parasite’s acidic food vacuole. The eventual destruction of red blood cells leads to life-threatening anemia. Consequently, malaria claims the lives of over 400,000 people per year, mostly children under the age of five in sub-Saharan Africa.

How chloroquine kills Plasmodium parasites has long been the subject of research. The drug is capable of binding to heme, which is a toxic byproduct of hemoglobin digestion. The parasite avoids the toxic effects of heme by stacking the molecules into an inert crystal called hemozoin. But when chloroquine binds to heme, hemozoin cannot be made, forcing the parasite to die in its own waste. Further supporting this idea is the fact that chloroquine concentrates in acidic cellular compartments, such as the parasite’s food vacuole.

But a virus is nothing like Plasmodium, begging the question of how chloroquine could possibly affect it. A virus is not even a cell — it is merely a small strand of DNA or RNA encapsulated in a bubble-like membrane of lipid and protein. After viruses invade, they co-opt the host cell’s machinery to reproduce themselves. They are the ultimate unwanted guest, depleting the host cell’s resources to make copies of themselves — virus babies, if you will.

The exploration of chloroquine as a potential antiviral agent has been ongoing for quite some time. A study in 2005 showed that chloroquine prevented the spread of SARS CoV in cultured cells (SARS CoV is a similar respiratory virus that caused the 2002 outbreak).

A study this February showed that chloroquine inhibited SARS-CoV-2 in cultured cells as well as a small cohort of about 100 patients with COVID-19. In addition, a new clinical trial underway in France recently released news that a combination drug therapy employing chloroquine showed significant reduction of the virus in the 20 patients treated so far.
So how does chloroquine thwart coronavirus? When a virus replicates inside a host cell, its pieces get made and processed by the host cell’s manufacturing system. A major part of this protein processing center is a compartment called the Golgi apparatus, which releases those proteins within acidic vesicles called endosomes. Endosomes then deliver this protein cargo to other places, including the cell surface. Viruses can hijack this system to process and release their babies from the host cell. In addition, SARS CoV enters a host cell through an endosome vesicle formed from the host cell’s surface membrane.

Recall that chloroquine concentrates inside acidic cellular compartments. It can get into Plasmodiums food vacuole, but it also concentrates inside a cell’s endosomes, which are used by viruses both when they enter and exit a host cell. Chemically, chloroquine is a weak base, sufficient to raise the pH in these compartments. As endosomes become less acidic, the proteins inside are ruined — they unfold because they are no longer at the correct pH. What this means for coronavirus is that its viral proteins are rendered nonfunctional because chloroquine changed the pH of the endosomes carrying them.

In addition to ruining the viral invader’s proteins, chloroquine can distort the shape of proteins called cytokines, which can reside in the endosomes of immune cells that fight infection. Sometimes, the immune system gets too excited and creates what is called a “cytokine storm,” which has been a major complication of COVID-19. By quelling this cytokine storm, chloroquine provides a dual advantage in helping the body combat coronavirus infection.

Chloroquine has been used for decades and has a reputation for being extraordinarily safe, although it is not used in patients with epilepsy, myasthenia gravis, or glucose-6-phosphate dehydrogenase deficiency. Chloroquine can also cause severe reactions in patients with psoriasis.

This would not be the first time chloroquine has been “repurposed” to treat a condition other than malaria. As noted, chloroquine can settle the immune system; in other words, it has anti-inflammatory properties. Consequently, the drug has been useful in treating inflammatory diseases, such as rheumatoid arthritis and lupus erythematosus.

If these promising initial results continue to hold up, chloroquine could possibly offer a cheap and safe treatment for those suffering from COVID-19.

Bill Sullivan

Bill Sullivan is a professor at Indiana University School of Medicine and the author of several books.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Chocolate’s secret ingredient

Chocolate’s secret ingredient

April 10, 2021

It’s the fermenting microbes that make it taste so good.

Unraveling the mind’s eye — science through a novel lens

Unraveling the mind’s eye — science through a novel lens

April 8, 2021

By exploring the intersection of art, vision loss and science, Erica Tandori creates multisensory displays to articulate the findings of biological research.

Lessons from plants: A changing environment

Lessons from plants: A changing environment

April 7, 2021

Beronda Montgomery writes about plants adapt to environmental conditions in this excerpt from her new book.

From the journals: JLR
Journal News

From the journals: JLR

April 6, 2021

A new toolkit for lipid biochemists. Using genomics to identify plasma lipid traits. Finding the sites that control lipid metabolism. Read about recent papers on these topics in the Journal of Lipid Research.

How effective is the first shot of the Pfizer or Moderna vaccine?

How effective is the first shot of the Pfizer or Moderna vaccine?

April 4, 2021

As the COVID-19 vaccines reach more people across the country, some people ask: Could we delay second doses to allow more people to be vaccinated more quickly?

Scientists seek COVID treatment answers in cheap, older drugs

Scientists seek COVID treatment answers in cheap, older drugs

April 3, 2021

Philanthropies are funding studies of medications like the antidepressant fluvoxamine. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.